NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHIBROXIN (norfloxacin) is a fluoroquinolone antibiotic ophthalmic solution approved for topical eye infections. It is administered as drops directly to the eye to treat bacterial conjunctivitis and corneal ulcers. The drug works by inhibiting bacterial DNA gyrase, preventing bacterial replication in ocular tissues.
LOE Approaching
LOE-approaching status indicates declining brand support and potential team consolidation; roles focus on optimizing remaining exclusivity and preparing for generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHIBROXIN offers exposure to ophthalmic market dynamics and mature product management, but limited growth trajectory given LOE-approaching status. Career advancement typically requires transition to earlier-stage pipeline products or lateral moves within Merck's ophthalmology portfolio.
Brand ManagerField Sales Representative
Worked on CHIBROXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.